Share:
Peer-Reviewed Publication
Radiother Oncol2020;144152-158.March 1, 2020Journal Article

Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning.

Jordan Wong1, Allan Fong2, Nevin McVicar3, Sally Smith4, Joshua Giambattista5, Derek Wells6, Carter Kolbeck7, Jonathan Giambattista8, Lovedeep Gondara9, Abraham Alexander10
1BC Cancer - Vancouver Center, Canada. Electronic address: Jordan.wong@bccancer.bc.ca.
2BC Cancer - Vancouver Center, Canada. Electronic address: allan.fong1@bccancer.bc.ca.
3BC Cancer - Vancouver Center, Canada. Electronic address: mcvicarn@rvh.on.ca.
4BC Cancer - Victoria Center, Canada. Electronic address: ssmith11@bccancer.bc.ca.
5Saskatchewan Cancer Agency, Regina, Canada; Limbus AI Inc., Regina, Canada. Electronic address: joshua.giambattista@saskcancer.ca.
6BC Cancer - Victoria Center, Canada. Electronic address: DWells@bccancer.bc.ca.
7Limbus AI Inc., Regina, Canada. Electronic address: carter@limbus.ai.
8Limbus AI Inc., Regina, Canada. Electronic address: jon@limbus.ai.
9BC Cancer - Vancouver Center, Canada. Electronic address: Lovedeep.Gondara@bccancer.bc.ca.
10BC Cancer - Victoria Center, Canada. Electronic address: AAlexander3@bccancer.bc.ca.

Abstract

BACKGROUND: Deep learning-based auto-segmented contours (DC) aim to alleviate labour intensive contouring of organs at risk (OAR) and clinical target volumes (CTV). Most previous DC validation studies have a limited number of expert observers for comparison and/or use a validation dataset related to the training dataset. We determine if DC models are comparable to Radiation Oncologist (RO) inter-o…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.